A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Vildagliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Nov 2017 Status changed from recruiting to completed.
- 08 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
- 08 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.